Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Free Cash Flow (2019 - 2025)

Biodesix (BDSX) has disclosed Free Cash Flow for 7 consecutive years, with $692000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 114.02% year-over-year to $692000.0, compared with a TTM value of -$23.5 million through Dec 2025, up 54.64%, and an annual FY2025 reading of -$23.5 million, up 54.64% over the prior year.
  • Free Cash Flow was $692000.0 for Q4 2025 at Biodesix, up from -$8.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $809000.0 in Q2 2021 and bottomed at -$20.5 million in Q2 2024.
  • Average Free Cash Flow over 5 years is -$10.0 million, with a median of -$10.3 million recorded in 2021.
  • The sharpest move saw Free Cash Flow soared 118.23% in 2021, then crashed 1326.58% in 2022.
  • Year by year, Free Cash Flow stood at -$10.7 million in 2021, then dropped by 29.37% to -$13.9 million in 2022, then fell by 10.01% to -$15.3 million in 2023, then skyrocketed by 67.68% to -$4.9 million in 2024, then skyrocketed by 114.02% to $692000.0 in 2025.
  • Business Quant data shows Free Cash Flow for BDSX at $692000.0 in Q4 2025, -$8.9 million in Q3 2025, and -$6.6 million in Q2 2025.